AVR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Anteris Technologies (AVR) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the company has positive developments such as reduced financing risk and collaboration with Medtronic, the financial performance and lack of strong trading signals suggest a cautious approach. Holding the stock may be more prudent until further positive catalysts emerge.
The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 57.011, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level (6.296), with resistance at 6.793 and support at 5.8.
The company has initiated the global pivotal PARADIGM Trial and received FDA approval for the trial. Additionally, the $320M capital raise, including a strategic investment from Medtronic, reduces financing risk and validates the product's viability.
The company reported a significant net operating cash outflow of $77.8M in 2025 due to trial demands. Revenue dropped significantly by 42.18% YoY in Q4 2025, and there is no recent congress trading data or strong hedge fund/insider activity.
In Q4 2025, revenue dropped by 42.18% YoY to $310,000. However, net income improved by 50.72% YoY to -$29.2M, and EPS increased by 37.04% YoY to -0.74. Gross margin improved to 70.65%, up 15.35% YoY.
Barclays and Lake Street analysts have lowered their price targets to $17 and $15, respectively, citing the dilutive impact of recent financing. However, both maintain positive ratings (Overweight and Buy) due to reduced financing risk and Medtronic's involvement.
